Merck, a leading science and technology company, is launching a comprehensive Fertility Benefit program in October 2023 that will offer employees financial support for fertility treatments.
The program will be launched in eight markets: Germany, the United Kingdom, Switzerland, China, India, Taiwan, Brazil, and Mexico.
To date, The company offers similar benefits to employees in the United States, Canada, and Japan. An expansion of the offering to Merck employees in further countries is planned to start next year.
Belén Garijo, Chair of the Executive Board and CEO of Merck, said, “As a long-time leader and pioneer in fertility, we understand the tremendous emotional and financial burden infertility can have on individuals and families.”
“We are delighted that through our Fertility Benefit program, we can support our employees as they strive to fulfill their dream of parenthood”, Belén Garijo added.
Belén Garijo further said, “This is one example of how Merck prioritizes employee well-being and fosters a culture where all can belong, grow, and thrive.”
The new Fertility Benefit offer applies to Merck employees, irrespective of their marital status, and is also open to their partners.
A range of services, such as fertility tests, in vitro fertilization treatments, and hormonal treatments, can be covered. Apart from financial assistance, Merck offers employees facing infertility issues additional information services related to fertility disorders.
Merck has many decades of experience in the field of fertility medicine. Today the company is the global market leader in therapies for fertility treatment.
According to current estimates, more than five million babies have been born with the help of products from Merck. This number represents about half of all babies born through medically assisted reproduction since the birth of the first baby conceived through in vitro fertilization in 1978.
